Tarsus Pharmaceuticals, Inc. cotiza a 71.19 USD y tiene una capitalización bursátil de $3.3B. En los últimos 12 meses ha facturado $606M con un margen de flujo de caja libre del -4.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demod…
| Métrica | TARS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -15.7% | -38.6% | +22.9% |
| Net Margin | -14.7% | -33.6% | +18.8% |
| FCF Margin | -4.9% | -13.9% | +8.9% |
| ROE | -19.3% | -40.4% | +21.1% |
| ROA | -11.8% | -32.0% | +20.2% |
| Current Ratio | 3.85 | 2.84 | +1.01 |
| Debt / Equity | 0.21 | 0.28 | -0.07 |